Product Description
Anti-FGF23 Fully Human Antibody for X-linked Hypophosphatemia (XLH). (Sourced from: https://www.kyowakirin.com/what_we_do/pdf/pipeline_e20240331.pdf)
Mechanisms of Action: FGF23 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Kirin, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|